Literature DB >> 22052787

High daily fraction dose external radiotherapy for T1 glottic carcinoma: treatment results and prognostic factors.

Melis Gultekin1, Enis Ozyar, Mustafa Cengiz, Gokhan Ozyigit, Mutlu Hayran, Sefik Hosal, Fadil Akyol.   

Abstract

BACKGROUND: The purpose of this study was to investigate the prognostic factors and treatment results of T1N0M0 glottic laryngeal carcinoma irradiated with 2.3 Gray (Gy) per fraction.
METHODS: A total of 183 patients with glottic carcinoma treated between June 1998 and January 2007 were retrospectively evaluated. Of the 183 patients, 163 patients (89%) had T1a and 20 patients (11%) had T1b disease. All patients received 2.3 Gy per fraction to a median total dose of 64.4 Gy.
RESULTS: The median follow-up was 63 months. The 5-year overall survival (OS), local control, and cancer-specific survival rates were 89%, 81%, and 90%, respectively. Multivariate analysis showed overall treatment time and age to be significant prognostic factors for local control and OS. We observed no grade IV or grade V acute toxicity. Trachea-esophageal fistula as late toxicity was observed in only 1 patient.
CONCLUSIONS: High daily fraction scheme seems to be a feasible schedule for early glottic carcinomas.
Copyright © 2011 Wiley Periodicals, Inc.

Entities:  

Mesh:

Year:  2011        PMID: 22052787     DOI: 10.1002/hed.21860

Source DB:  PubMed          Journal:  Head Neck        ISSN: 1043-3074            Impact factor:   3.147


  6 in total

1.  [Non- inferior moderate hypofractionated irradiation of glottis T1/T2 laryngeal cancer ].

Authors:  Martina Becker-Schiebe; Hans Christiansen
Journal:  Strahlenther Onkol       Date:  2014-07       Impact factor: 3.621

Review 2.  Therapeutic modalities and oncologic outcomes in the treatment of T1b glottic squamous cell carcinoma: a systematic review.

Authors:  Federico Maria Gioacchini; Michele Tulli; Shaniko Kaleci; Stefano Bondi; Mario Bussi; Massimo Re
Journal:  Eur Arch Otorhinolaryngol       Date:  2017-09-19       Impact factor: 2.503

3.  Outcomes of carotid-sparing IMRT for T1 glottic cancer: Comparison with conventional radiation.

Authors:  Abdallah S R Mohamed; Blaine D Smith; Joshua B Smith; Parag Sevak; Jessica S Malek; Aasheesh Kanwar; Theodora Browne; G Brandon Gunn; Adam S Garden; Steven J Frank; William H Morrison; Jack Phan; Mark Zafereo; Heath Skinner; Stephen Y Lai; Katherine A Hutcheson; Jan S Lewin; Amy E Hessel; Apurva A Thekdi; Randal S Weber; Clifton D Fuller; David I Rosenthal
Journal:  Laryngoscope       Date:  2019-02-12       Impact factor: 3.325

4.  Radiotherapy with fraction size of 2.25 Gy in T1-2 laryngeal and hypopharyngeal cancer.

Authors:  Kumiko Karasawa; Hiroaki Kunogi; Takahisa Hirai; Hidehiro Hoji; Hisako Hirowatari; Hiromi Izawa; Kana Ito; Keisuke Sasai; Tomohisa Furuya; Shuichi Ozawa; Fumihiko Matsumoto; Shin Ito; Shinichi Oba
Journal:  J Radiat Res       Date:  2013-01-07       Impact factor: 2.724

Review 5.  Involvement of the Anterior Commissure in Early Glottic Cancer (Tis-T2): A Review of the Literature.

Authors:  Martine Hendriksma; Elisabeth V Sjögren
Journal:  Cancers (Basel)       Date:  2019-08-23       Impact factor: 6.639

6.  Short treatment time and excellent treatment outcome in accelerated hyperfractionated radiotherapy for T1 glottic cancer.

Authors:  Yukihisa Tamaki; Yoko Hieda; Rika Yoshida; Takeshi Yoshizako; Takafumi Fuchiwaki; Noriaki Aoi; Kazumasa Sekihara; Kazuhiro Kitajima; Hideyuki Kawauchi; Hajime Kitagaki; Ryohei Sasaki; Taisuke Inomata
Journal:  Nagoya J Med Sci       Date:  2015-11       Impact factor: 1.131

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.